Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

A Single-arm Dose-finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE225 in Combination With Nilotinib in Chronic or Accelerated Phase of Chronic Myeloid Leukemia Patients Who Have Failed Prior Therapy With Other BCR-ABL Tyrosine-kinase Inhibitors

NCT01456676•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the feasibility of administering the combination of nilotinib and LDE225 to patients with chronic or accelerated phase of chronic myeloid leukemia and to establish the maximum tolerated dose (MTD) and/or recommended Phase II dose level (RP2D) of LDE225 in combination with nilotinib.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Philadelphia chromosome positive (Ph+) CML in chronic phase (CP) or accelerated phase (AP)with resistance to at least one prior BCR-ABL targeting TKI
•2. Documented chronic phase CML
•3. Adequate end organ function
•4. Female patients of childbearing potential must have a negative serum pregnancy test and must be using highly effective methods of contraception. Male patients with female partners of child-bearing potential must use condoms.

Exclusion Criteria

•1. Impaired cardiac function
•2. Severe and/or uncontrolled concurrent disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
•3. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
•4. Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to entering the study
•5. Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either safely discontinued or switched to a different medication prior to starting study drug.
•6. Previously documented BCR-ABL Y253H, E255K/V, T315I or F359C/V mutation

Locations (7)

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Marseille, France

Novartis Investigative Site

Frankfurt, Germany

Novartis Investigative Site

Ulm, Germany

Novartis Investigative Site

Roma, RM, Italy

Novartis Investigative Site

Pamplona, Navarre, Spain

Novartis Investigative Site

Madrid, Spain

Key Dates

Start Date

January 1, 2012

Primary Completion Date

February 1, 2014

Completion Date

February 1, 2014

Last Updated

December 9, 2020

Enrollment

ACTUAL participants

Conditions

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Interventions

Nilotinib + LDE225

DRUG